2-Propen-1-one, 3-[(1R,4R)-5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-1-phenyl-, (2E)- manufacturers
- BRG1-IN-1
-
- $1980.00
-
2026-05-11
- CAS:2616813-99-9
- Purity:
- Supply Ability: 10g
|
| | 2-Propen-1-one, 3-[(1R,4R)-5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-1-phenyl-, (2E)- Basic information |
| | 2-Propen-1-one, 3-[(1R,4R)-5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-1-phenyl-, (2E)- Chemical Properties |
| Boiling point | 478.0±45.0 °C(Predicted) | | density | 1.284±0.06 g/cm3(Predicted) | | pka | 7.05±0.40(Predicted) |
| | 2-Propen-1-one, 3-[(1R,4R)-5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-1-phenyl-, (2E)- Usage And Synthesis |
| Uses | BRG1-IN-1 (Compound 11d) is a potent inhibitor of SMARCA4/BRG1. BRG1-IN-1 shows better efficacy than PFI-3 in sensitizing GBM cells to the antiproliferative and cell death inducing effects of Temozolomide in vitro. BRG1-IN-1 enhances the inhibitor effect of Temozolomide on the growth of subcutaneous GBM tumors[1]. | | References | [1] He Y, et al. Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells. Bioorg Med Chem. 2022 Jan 1;53:116533. DOI:10.1016/j.bmc.2021.116533 |
| | 2-Propen-1-one, 3-[(1R,4R)-5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-1-phenyl-, (2E)- Preparation Products And Raw materials |
|